Insys Therapeutics Inc (INSY) reported quarterly earnings results on Thursday, Apr-28-2016. The company said it had a profit of $0.11 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $0.10. The company posted revenue of $62.00 million in the period, compared to analysts expectations of $61.31 million. The company’s revenue was down -12.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 EPS.
Many Wall Street Analysts have commented on Insys Therapeutics Inc. Shares were Reiterated by Jefferies on Apr 12, 2016 to “Buy” and Lowered the Price Target to $ 17 from a previous price target of $23 .Shares were Reiterated by Piper Jaffray on Apr 11, 2016 to “Overweight” and Lowered the Price Target to $ 28 from a previous price target of $46 .Shares were Reiterated by Jefferies on Feb 24, 2016 to “Buy” and Lowered the Price Target to $ 23 from a previous price target of $36 .
Insys Therapeutics Inc closed down -0.88 points or -5.71% at $14.52 with 4,12,652 shares getting traded on Wednesday. Post opening the session at $15.19, the shares hit an intraday low of $14.51 and an intraday high of $15.5281 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Mar 7, 2016, Patrick Fourteau (director) sold 15,000 shares at $18.22 per share price. According to the SEC, on Mar 4, 2016, Theodore H Stanley (director) sold 20,000 shares at $18.11 per share price. On Nov 18, 2015, John N Kapoor (CEO) purchased 5,000 shares at $29.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.